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ABSTRACT
Introduction: Excess adiposity contributes to
cardiometabolic disease. Although adipose
depots can be measured using imaging,
implementation remains limited in practice.
Data comparing surrogate indices of total and
visceral adiposity with gold standard
measurements in the context of a clinical trial
population are lacking. We explored the
relationships between adipose distribution
indices and imaging assessments of body
composition using baseline data from the
EMPA-REG H2H SUTM trial.
Methods: 118 participants from the Phase III
trial of empagliflozin 25 mg vs. glimepiride
1–4 mg enrolled in a dedicated sub-study
underwent assessment of total fat and fat-free
mass by dual x-ray absorptiometry (n = 93) and
abdominal visceral (VAT) and subcutaneous
adipose tissue by magnetic resonance imaging
(n = 99). Correlations with waist circumference
(WC), estimated total body fat (eTBF), index of
central obesity (ICO), and visceral adiposity
index (VAI) were assessed.
Results: eTBF was highly representative of total
body fat (Spearman’s q = 0.73, P\0.001) but
not associated with VAT. WC and ICO were
strongly, and VAI to a lesser degree, correlated
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with VAT (q = 0.66, P\0.001; q = 0.52,
P\0.001; q = 0.24, P = 0.02, respectively).
Conclusion: These findings support the use of
eTBF and WC or ICO as surrogate indices for
total body fat and VAT, respectively, in the
absence of gold standard imaging methodology.
Keywords: Body fat distribution;
Empagliflozin; Obesity; Sodium glucose
co-transporter 2 inhibitor; Visceral adipose
tissue
INTRODUCTION
Total body fat content, as measured by dual
X-ray absorptiometry (DXA), is highly
correlated with multiple metabolic risk factors
[1]. Intra-abdominal (visceral) adipose tissue
(VAT) also influences cardiometabolic risk
factors independent of total body fat and is a
major risk factor for many of the
cardiometabolic complications of obesity
[2–6]. Although various adipose depots can be
accurately measured using dedicated imaging
techniques, implementation of these modalities
remain limited in clinical practice due to high
cost, radiation exposure, and prolonged scan
time. Multiple surrogate indices of total and
visceral adiposity have been developed that do
not require advanced imaging, have been
validated with metabolic outcomes, and are
more readily applied in the clinical setting
[7–9]. Furthermore, the individual parameters
used to derive these indices can be applied
across a broad spectrum of populations.
Empagliflozin (EMPA) is a potent and
selective sodium glucose cotransporter 2
inhibitor [10]. In a Phase III, randomized,
double-blind trial (EMPA-REG H2H SUTM,
ClinicalTrials.gov NCT01167881) in 1549
patients with type 2 diabetes (T2D), EMPA
25 mg daily as add-on to metformin for
104 weeks led to sustained reductions in
Glycosylated hemoglobin (HbA1c), body
weight [MMRM-adjusted mean change from
baseline -4.6 (95% CI -5.0, -4.2) kg,
P\0.0001], and blood pressure compared with
glimepiride 1–4 mg [11]. In an embedded,
dedicated body composition sub-study,
reductions in trunk fat, limb fat, total fat
mass, VAT [adjusted mean change from
baseline -22.2 (95% CI -37.1, -7.4) cm3,
P = 0.004], and abdominal subcutaneous
adipose tissue [SAT; adjusted mean change
from baseline -40.0 (95% CI -58.9, -21.1)
cm3, P\0.0001] were demonstrated with EMPA
compared with glimepiride [11]. EMPA has also
been shown to reduce body weight and
surrogate indices of total and visceral adiposity
at 12 and 24 weeks among 3300 patients with
T2D enrolled in five clinical trials [12].
Data comparing adipose distribution indices
with gold standard body composition
measurements within the context of an
extensively phenotyped clinical trial
population with highly standardized
assessments are lacking. We aimed to explore
the relationships between adipose distribution
indices and direct imaging assessments of body
composition using baseline data from the
EMPA-REG H2H SU trial.
METHODS
The EMPA-REG H2H SU trial was a
double-blind, randomized, active-control trial
of EMPA 25 mg daily vs. glimepiride 1–4 mg
daily as add-on to metformin among adults
with T2D and HbA1c concentrations of 7–10%
for 104 weeks. All patients at sites choosing to
contribute to a dedicated body composition
sub-study were offered participation and signed
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separate informed consent forms. Whole body
DXA and regional magnetic resonance imaging
(MRI) scans (involving one axial slice from T1
sequence with and without fat suppression at
the level of L4–L5 intervertebral disc) were
performed [11]. Scans were obtained in a
standardized manner and assessed by an
independent reviewer. Using Spearman’s rank
correlation coefficients, we assessed the
correlations between gold standard body
composition assessments—total fat mass and
fat-free mass based on DXA and abdominal VAT
and SAT based on MRI—and indices of total and
visceral adiposity at baseline. Indices assessed
included waist circumference (WC, cm);
estimated total body fat [eTBF; Young man’s
Christian association (YMCA) formula] [13, 14]:
100 9 (-98.42 ? [4.15 9 WC (in)]-[0.082 9
weight (lbs.)])/weight for men and
100 9 (-76.76 ? [4.15 9 WC]-[0.082 9 weight])/
weight for women; index of central obesity
(ICO): WC/height [9]; and visceral adiposity
index (VAI) [15]: (WC (cm)/[39.68 ?
(1.88 9 BMI)]) 9 (TG/1.03) 9 (1.31/HDL-C) for
men; (WC/[36.58 ? (1.89 9 BMI)]) 9 (TG/0.81) 9
(1.52/HDL-C) for women, where BMI is body
mass index (kg/m2), TG is triglycerides
(mmol/L) and HDL-cholesterol is high-density
lipoprotein cholesterol (mmol/L). Correlations
(positive or negative) were classified as
negligible if 0.0–0.3, mild if 0.3–0.5, moderate
if 0.5–0.7, and high if 0.7–0.9 [16]. For all
statistical testing, a 2-sided P value\0.05 was
considered statistically significant. All statistical
analyses were performed using SAS version 9.2
software (SAS Corporation, Cary, NC).
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
the patients for being included in the study.
RESULTS
Baseline characteristics of 118 patients with a
baseline DXA (n = 93) or MRI (n = 99) scan are
shown in Table 1. Patients with a baseline scan
had a mean age of 55.6 years and were
predominantly female and white. Body
weight, WC, eTBF, ICO, and VAI were similar
between DXA and MRI scanned groups.
WC was mildly correlated with percent total
body fat (Spearman’s q = 0.31, P = 0.002) and
fat-free mass (Spearman’s q = 0.44, P\0.001)
but moderately correlated with VAT
(Spearman’s q = 0.66, P\0.001, Fig. 1a) and
SAT (Spearman’s q = 0.55, P\0.001). eTBF was
highly correlated with total body fat
(Spearman’s q = 0.73, P\0.001, Fig. 1b) and
moderately correlated with SAT (Spearman’s
q = 0.51, P\0.001), but not significantly
associated with VAT. ICO was moderately
correlated with total body fat (Spearman’s
q = 0.61, P\0.001), VAT (Spearman’s q = 0.52,
P\0.001, Fig. 1c), and SAT (Spearman’s
q = 0.67, P\0.001), but not with fat-free mass.
VAI was negligibly correlated with VAT
(Spearman’s q = 0.24, P = 0.02, Fig. 1d) and
was not significantly associated with SAT.
DISCUSSION
In this post hoc analysis using a subset of the
1549 patients with T2D randomized to
treatment with EMPA vs. glimepiride in the
EMPA-REG H2H SU trial with baseline DXA or
MRI, we found that eTBF (using sex-specific
equations incorporating weight and WC) was
highly representative of total body fat mass by
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Table 1 Baseline characteristics of the study population with a baseline DXA or MRI scan
Baseline characteristics Patients with a DXA
scan (n 5 93)
Patients with an
MRI scan (n5 99)
Age (years) 55.6 (10.8) 55.6 (10.1)
Male (%) 39 (41.9) 46 (46.5)
Race (%)
White 74 (79.6) 81 (81.8)
Asian 17 (18.3) 14 (14.1)
Black 2 (2.2) 4 (4.0)
Time since T2D diagnosis (years)
B1 12 (12.9) 9 (9.1)
[1–5 35 (37.6) 45 (45.5)
[5–10 27 (29.0) 23 (23.2)
[10 19 (20.4) 22 (22.2)
HbA1c (%) 8.19 (1.02) 8.20 (0.99)
Fasting glucose (mg/dL) 159.3 (45.9) 161.7 (47.2)
Triglycerides (mg/dL) 183.0 (116.1)a 216.3 (259.6)d
HDL cholesterol (mg/dL) 46.4 (10.6)a 45.2 (10.6)d
LDL cholesterol (mg/dL) 96.0 (31.3)a 97.4 (32.0)e
Total cholesterol (mg/dL) 177.8 (38.9)a 181.5 (43.7)d
AST (U/L) 26.7 (19.4)a 26.6 (17.8)d
ALT (U/L) 34.1 (25.6)a 34.9 (25.4)d
Body weight (kg) 84.1 (15.2) 87.4 (16.3)
Body mass index (kg/m2) 31.9 (4.9) 32.4 (4.9)
Waist circumference (cm) 103.9 (12.1) 106.1 (12.3)
Est total body fat (%) 37.4 (9.9) 37.1 (9.6)
Index of central obesity 0.64 (0.08) 0.65 (0.08)
Visceral adiposity index 3.3 (3.1)a 4.4 (8.5)d
Total fat mass (%) 38.4 (8.4) 38.9 (8.0)b
Fat-free mass (kg) 50.8 (10.7) 50.7 (11.2)b
Visceral fat mass (cm2) 164.1 (81.3)b 174.0 (80.7)
Abdominal subcutaneous fat mass (cm2) 338.4 (107.6)c 342.2 (111.4)
Data are mean (standard deviation) or n (%).
DXA dual x-ray absorptiometry, MRI magnetic resonance imaging, T2D Type 2 diabetes, HbA1c glycosylated hemoglobin,
HDL high-density lipoprotein, LDL low-density lipoprotein, AST Aspartate transaminase, ALT Alanine transaminase
Subjects with data available: a n = 92; b n = 74; c n = 73; d n = 98; e n = 97
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DXA, but not associated with visceral adiposity
by MRI. By contrast, WC and ICO had the
strongest relation to regional abdominal
adiposity with VAT and SAT. Surprisingly, VAI
was not highly correlated with MRI-based
assessment of VAT. These findings support the
use of eTBF for non-imaging estimations of total
body fat and the use of WC or ICO as surrogate
indices for abdominal VAT and SAT for both
clinical and research purposes in the absence of
gold standard methodology.
The eTBF index used in this study derives
from the popularly termed YMCA formula,
referencing the community fitness
organization for which these formulas were
once likely utilized in a training handbook.
The origin of the eTBF index can be traced to
the research of Wilmore and Behnke who used
anthropometric measurements from multiple
body sites to estimate body composition
variables from regression equations among
healthy college student volunteers [13, 14].
eTBF is relatively simple to calculate and is
one of many anthropometry-based estimated
body fat formulas currently in use. Our finding
that eTBF was strongly correlated with total
body fat by DXA, but not significantly
associated with VAT by MRI (despite
incorporation of WC as a derivation variable),
supports its use as a surrogate for total body fat,
but not abdominal adiposity, in the absence of
DXA imaging. Whether eTBF is a better
predictor of total body fat compared with
other methods of body fat quantification
remains to be seen.
WC has traditionally been considered one of
the most valid indices of regional adipose tissue
distribution with excellent correlation with
Fig. 1 Correlations between a waist circumference and
VAT; b estimated total body fat and total fat mass by
DXA; c index of central obesity and VAT; and d visceral
adiposity index and VAT. DXA dual x-ray absorptiometry,
VAT visceral adipose tissue
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VAT by abdominal imaging (correlation
coefficient = 0.77 among 151 metabolically
healthy men and women) [17]. It also has a
strong association with cardiovascular disease
risk and mortality [18]. As a result, the American
Heart Association/National Heart, Lung, and
Blood Institute has incorporated WC as a
surrogate marker of abdominal/central obesity
in their diagnostic definition of the metabolic
syndrome [19]. ICO, the index of WC to height,
has also been extensively studied and may be
superior to WC in predicting multiple
cardiovascular risk factors in both sexes and
different ethnic groups [20]. However, WC is
limited as a surrogate for the VAT phenotype.
First, the correlation between WC and VAT is
highly variable among different racial groups,
prompting the International Diabetes
Federation to define different cutoffs for
abnormal WC in Asian populations [21].
Nevertheless, we still observed a strong
correlation between WC and VAT in our
population with a significant proportion of
Asian patients. Second, WC measurement
includes both VAT and abdominal SAT
compartments. These two depots are
anatomically and physiologically distinct,
especially within the obese population, and
are differentially associated with markers of
cardiometabolic risk [3]. Nevertheless, our
findings demonstrate strong correlations
between WC and ICO and VAT among an
ethnically diverse population with T2D,
supporting their use when direct imaging
assessments are not available.
VAI is a mathematical model-derived index
based on both anthropometric and
laboratory-based correlates of excess adiposity.
It has been shown to positively associate with
peripheral glucose utilization during
euglycemic hyperinsulinemic clamp and
(expectedly given its derivation) is correlated
with cardiovascular risk [15]. However, we
found that the correlation between VAI and
VAT as assessed by MRI was negligible,
suggesting it does not sufficiently reflect the
anatomic burden of VAT to warrant its use as a
surrogate for clinical or research purposes.
Further research should confirm these findings
in varying populations with different
demographic and clinical phenotypes.
Several study limitations merit comment.
First, we are unable to report on the association
of waist-hip ratio with direct imaging
phenotypes as hip circumference was not
measured in our study. Second, subgroup
analyses by sex and age were not performed
due to a limited sample size and the concern
that multiple subgroup analyses on a limited
patient sample may substantially increase the
probability of false-positive findings [22].
Further research should focus on validating
these indices within larger, more diverse
populations, including age- and sex-specific
analyses given their strong influence on
adipose distribution.
CONCLUSIONS
In conclusion, using baseline data from the
EMPA-REG H2H SU trial, we found strong
correlations between the adipose distribution
indices of eTBF (YMCA formula) and total body
fat by DXA and between WC and ICO and
abdominal VAT and SAT by MRI. These findings
support their use as surrogate measurements for
clinical and research purposes in the absence of
gold standard direct imaging assessments of body
fat composition. Analyses of the recently
reported EMPA-REG OUTCOMETM trial
(NCT01131676) [23] demonstrating decreased
cardiovascular mortality of EMPA compared with
placebo in a high-cardiovascular risk patient
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population may establish whether changes in
such indices after EMPA treatment are associated
with improved clinical outcomes.
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